Prognostic significance of p53 in the cancer of the larynx

Anticancer Research

Volumn 20, Issue 5 B, 2000, Pages 3555-3564

  Assimakopoulos, D ^a   Kolettas, E ^a   Zagorianakou, N ^a   Evangelou, A ^a   Skevas, A ^a   Agnantis, N J ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Laryngeal cancer; p53; Prognosis

Indexed keywords

PHOSPHOPROTEIN; PROTEIN P53; TRANSCRIPTION FACTOR; TUMOR MARKER;

CANCER INHIBITION; CELL CYCLE; DISEASE MARKER; DRUG TARGETING; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; LARYNX CANCER; MOLECULAR GENETICS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SQUAMOUS CELL CARCINOMA;

GENES, P53; HUMANS; LARYNGEAL NEOPLASMS; PROGNOSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033635641     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (107)

1. The p 53 tumour suppressor gene
2. p53: Puzzle and paradigm
3. p53, the cellular gatekeeper for growth and division
4. The p 53 pathway
5. Tumor suppressor p53: Regulation and function
6. Montesano R and Harris CC: Database of p53 gene somatic mutations in human tumours and cell lines
7. Montesano R: IARC database of p53 gene mutations in human tumours and cell lines: Updated compilation, revised formats and new visualisation tools
8. Exploiting the p53 pathway for cancer diagnosis and therapy
9. NDM2 - Arbiter of p53£ destruction
10. The p53 tumour suppressor gene and tumour prognosis: Is there a relationship?
11. Otolaryngology head and neck surgery
12. Evaluation of cancer risk in tobacco chewers and smokers: An epidemiologic assessment
13. The effect of joint exposure to alcohol and tobacco risk on cancer of the mouth and pharynx
14. Synergistic effect of alcohol on epidermoid carcinogenesis in the larynx
15. Interaction of alcohol and tobacco in laryngeal cancer
16. Pathologic and cytometric indicators of biologic behaviour in laryngeal cancer
17. Mdm 2 promotes the rapid degradation of p53
18. Regulation of p 53 stability by mdm2
19. Definition of a consensus binding site for p 53
20. Four p53 DNA-binding domain peptides bind natural p 53 response elements and bend DNA
21. Interaction of p53 with its consensus DNA-binding
22. Structure of the p 53 tumour suppressor bound to the ankyrin and SH3 domains of 53BP2
23. p53 and its 14Kda C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches
24. Structural aspects of the p53 protein in relation to gene evolution: A second look
25. New insights into p 53 function from structural studies
26. p53: Integrating the complexity
27. p53 tumour suppressor gene: From the basic research laboratory to the clinic - An abridged histirical perspective
28. The p 53 network
29. Accumulation of p 53 in a mutant cell line defective in the ubiquitin pathway
30. Negative feedback regulation of the wild-type p 53 biosynthesis
31. Requirement of p 53 and p21 to sustain G2 arrest after DNA damage
32. WAF 1, a potential mediator of p53 tumour suppression
33. p21WAF1 is necessary for the p53-mediated G 1 arrest in human cancer cells
34. Roles of p53 in growth arrest and apoptosis: Putting on the breaks after genotoxic stress
35. Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair
36. Evidence for a second cell cycle block at G2/M by p 53
37. Cell cycle checkpoints: Preventing an identity crisis
38. p53 regulates G2 checkpoint through cyclin B1
39. p53-dependent apoptosis in the absence of p53-target genes
40. Induction of apoptosis in HeLa cells by transactivation-deficient p 53
41. Tumour suppressor p 53 is a direct transcriptional activator of the human bax gene
42. Wild-type human p53 and a temperature sensitive mutant induce fas/APO 1 expression
43. Regulated targeting of bax to mitochondria
44. Bax-induced cytochrome C release from mitochondria is independent of the permeability transition pore but highly dependent on Mg2+ ions
45. Mice deficient for p 53 are developmentaly normal but susceptible to spontaneous tumours
46. High incidence of lung, bone and lymph tumours in transgenic mice overexpressing mutant alleles of p 53 oncogene
47. The p53-mdm 2 autoregulatory feedback loop
48. Point mutations and nucleotide insertions in the MDM 2 zinc finger structure of human tumours
49. Molecular themes in oncogenesis
50. The molecular basis of oncogenes and tumour suppressor genes
51. The hallmarks of cancer
52. p53 mutations in Barrettes epithelium and esophageal cancer
53. p53 mutations and protein accumulation during multistage human esophageal carcinogenesis
54. High frequency of p 53 alterations associated with protein overexpression in human squamous cell carcinoma of the larynx
55. Occurrence of p 53 gene deletions and human papilloma virus infection in human head and neck cancer
56. Assessment of p53 protein expression in normal, begign and malignant oral mucosa
57. p53 overexpression is an early event in the development of human squamous cell carcinoma of the larynx: Genetic and prognostic implications
58. Discordant p 53 gene mutations in primary head and neck cancers and corresponding second primary cancers of the upper digestive tract
59. The role of p 53 tumour suppressor gene in squamous cell carcinoma of the head and neck
60. The incidence of p 53 mutations increases with progression of head and neck cancer
61. Overexpression of p 53 in human laryngeal carcinoma
62. p53 expression in laryngeal carcinoma
63. Prognostic factors in laryngeal carcinoma. A multi factorial study of 416 cases
64. p53 expression in normal, dysplastic and neoplastic laryngeal epithelium, absence of a correlation with prognostic factors
65. Overexpression of tumour suppressor gene p 53 in laryngeal squamous cell carcinomas and its prognostic significance
66. p53 protein expression in laryngeal squamous cell carcinomas bearing wild-type and mutated p 53 gene
67. Prognostic significance of clinical factors and p 53 expression in patients with glottic carcinoma treated with radiation therapy
68. Over-expression of p 53 protein in benign and malignant laryngeal epithelial lesions
69. p53 overexpression in laryngeal carcinoma is not predictive of response to radiotherapy
70. p53 immunostaining and image cytometry DNA analysis in precancerous and cancerous squamous epithelial lesions of the larynx
71. Overexpression of p 53 nuclear protein in premalignant and malignant laryngeal lesions
72. p53 protein expression in tumours from head and neck subsites, larynx and hypopharynx, and differences in relationship to survival
73. Overexpression of p53 in laryngeal carcinoma: Clinopathological implications
74. Clinical relevance of 53 and bc1-2 protein over-expression in laryngeal squamous cell carcinoma
75. Multiple genetic lesions in laryngeal squamous cell carcinomas
76. Tumour suppressor p 53 gene mutation in squamous cell carcinoma of the larynx
77. High incidence of p53 alterations (mutation, deletion, overexpression) in head and neck primary tumours and metastases: Absence of correlation with clinical outcome. Frequent protein overexpression in normal epithelium and in early non-invasive lesions
78. Mutation of p53 in squamous cell cancer of the head and neck: Relationship to tumour cell proliferation
79. Molecular analysis of p 53 gene in laryngeal premalignant and malignant lesions. P53 protein immunohistochemical expression is positively related to proliferating nuclear antigen labelling index
80. Radioresistance and p 53 status of T2 laryngeal carcinoma. Analysis by immunohistochemistry and denaturing gradient gel electrophoresis
81. Immunohistochemical and molecular analysis of bax, bc1- 2 and p53 genes in laryngeal squamous cell carcinomas
82. p53 mutation as a prognostic marker in advanced laryngeal carcinoma
83. Molecular assessment of p 53 abnormalities at the invasive front of oral squamous cell carcinomas
84. Immunologically distinct p53 molecules generated by alternative splicing
85. Amplification of gene encoding a p53-associated protein in human sarcoma
86. The role of p 53 tumour suppressor gene in human head and neck tumourigenesis
87. Most human squamous cell carcinomas in the oral cavity contain mutated p 53 tumour suppressor genes
88. Frequent p 53 mutations in head and neck cancer
89. Overexpression of p53 protein does not predict local-regional control or survival in patients with early-stage squamous cell carcinoma of the glottic larynx treated with radiotherapy
90. Is p53 an independent prognostic factor in patients with laryngeal carcinoma?
91. Antigen retrieval: p53 staining in benign, pre-malignant and malignant tissues of the larynx
92. Altered patterns of retinoblastoma gene product expression in benign, premalignant and malignant epithelium of the larynx: An immunohistochemical study including correlation with p53, bc1- 2 and proliferating indices
93. p53 genotyping - An effective concept for molecular testing of head and neck cancer?
94. Correlation of tumour markers p53, bc1-2, CD34, CD44H, CD44v6 and Ki- 67 with survival and metastasis in laryngeal squamous cell carcinoma
95. Immunochemical expression of cathepsin D in laryngeal lesions: Correlation with CD44 expression, p 53 and RB status and proliferation associated indices
96. Glycoprotein CD44 expression in benign, premalignant and malignant epithelial lesions of the larynx: An immunohistochemical study including correlation with RB, p53, Ki- 67 and PCNA
97. Immunohistochemical detection of p 53 in preneoplastic lesions and squamous cell carcinoma of the head and neck
98. p53 expression and cell proliferation as prognostic factors in laryngeal squamous cell carcinoma
99. Prognostic significance of p 53 gene mutations in laryngeal cancer
100. Mdm2: Ebig brother£ of p 53
101. Mdm2 oncoprotein overexpression in laryngeal squamous cell carcinoma: Association with wild-type p 53 accumulation
102. The predictive value of p53, mdm2, cyclin D1 and Ki67 in the progression from low-grade dysplasia towards carcinoma of the larynx
103. Amplification of cyclin D 1 and mdm2 in oesophageal carcinoma
104. mdm2 Expression correlates with wild-type p 53 status in oesophageal adenocarcinoma